Cryotherapy reduces oral mucositis and febrile episodes in myeloma patients treated with high-dose melphalan and autologous stem cell transplant: a prospective, randomized study

Marchesi, Francesco; Tendas, Andrea; Giannarelli, Diana; Viggiani, C.; Gumenyuk, Svitlana; Renzi, Daniela; Franceschini, Luca; Caffarella, G.; Rizzo, Manuela; Palombi, Francesca; Pisani, Francesco; Romano, Atelda; Spadea, Antonio; Papa, Elena; Canfora, Marco; Arcese, William; Mengarelli, Andrea

doi:10.1038/bmt.2016.207

Cited by 30 publications

(65 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Patients experienced cryotherapy under following conditions. First, eight studies (Askarifar et al, ; Gori et al, 2017; Lilleby et al, ; Marchesi et al, ; Salvador et al, ; Svanberg, Birgegard, & Ohrn, ; Svanberg, Ohrn, & Birgegard, ; Svanberg et al, ) targeted patients receiving high‐dose chemotherapy before blood stem cell transplantation in haematology malignancies. Second, six studies (Cascinu et al, ; Heydari, Shaifi, & Salek, ; Karagozoglu & Filiz Ulusoy, ; Katranci, Ovayolu, Ovayolu, & Sevinc, ; Papadeas et al, ; Sorensen et al, ) focused on general chemotherapy in solid tumours such as gastric and colorectal cancers.…”

Section: Resultsmentioning

confidence: 99%

“…Patients experienced cryotherapy under following conditions. First, eight studies (Askarifar et al, 2016;Gori et al, 2017;Lilleby et al, 2006;Marchesi et al, 2017;Salvador et al, 2012;Svanberg, Birgegard, & Ohrn, 2007;Svanberg, Ohrn, & Birgegard, 2010;Svanberg et al, 2012) targeted patients receiving high-dose…”

Section: General Characteristics Of Selected Studiesmentioning

confidence: 99%

“…Anti-cancer drugs used before blood stem cell transplantation were often melphalan (Askarifar et al, 2016;Lilleby et al, 2006;Marchesi et al, 2017;Salvador et al, 2012), and a mixture of melphalan and busulfan was partly used in some studies (Svanberg et al, 2007;Svanberg et al, 2010;Svanberg et al, 2012). Only one study (Gori et al, 2017) used methotrexate (MTX).…”

Section: General Characteristics Of Selected Studiesmentioning

confidence: 99%

“…The tools used for measuring the severity of oral mucositis were as follows. The tool most often used, in six studies, was the WHO scale for oral mucositis (Askarifar et al, 2016;Gori et al, 2017;Heydari et al, 2012;Katranci et al, 2012;Salvador et al, 2012;Svanberg et al, 2012); four studies used the Physician-Judged Mucositis Grading (Cascinu et al, 1994;Kakoei et al, 2013;Karagozoglu & Filiz Ulusoy, 2005;Papadeas et al, 2007); the National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI scale) was used for three studies (Lilleby et al, 2006;Marchesi et al, 2017;Sorensen et al, 2008); and the Oral Mucositis Assessment score (OMAS) was used in two studies (Svanberg et al, 2007;Svanberg et al, 2010).…”

Section: General Characteristics Of Selected Studiesmentioning

confidence: 99%

See 3 more Smart Citations

Meta‐analysis of oral cryotherapy in preventing oral mucositis associated with cancer therapy

Park

Lee

2019

Int J of Nursing Practice

View full text Add to dashboard Cite

Aims To review scientific evidence related to oral cryotherapy to prevent oral mucositis after cancer therapy. Background Oral mucositis is a common complication of cancer therapy. In the most severe form of oral mucositis, patients cannot eat or drink at all and must receive nutrition and fluid replacement through parenteral support. Topical cooling of the oral mucosa may be an option for the prevention of oral mucositis. Design Systematic review and meta‐analysis. Data sources The literature search was performed using the Ovid MEDLINE, Embase, Cochrane Library, and CINAHL Complete electronic databases for articles published up to 2017. The reference lists of all retrieved articles were manually reviewed to identify additional relevant studies. Results Of 353 publications, 15 randomized controlled trials, involving 919 cancer patients, conducted between 1994 and 2017 were included in the present meta‐analysis. Oral cryotherapy, applied during treatment of solid cancers, led to a statistically lower level (P < .05) of oral mucositis overall, and of the more severe grades (3‐4 and 2‐4). Conclusions Results of this study provide a scientific basis for oral cryotherapy as a viable nursing intervention that can significantly reduce the occurrence of severe oral mucositis.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: General Characteristics Of Selected Studiesmentioning

confidence: 99%

Section: General Characteristics Of Selected Studiesmentioning

confidence: 99%

Section: General Characteristics Of Selected Studiesmentioning

confidence: 99%

See 2 more Smart Citations

Meta‐analysis of oral cryotherapy in preventing oral mucositis associated with cancer therapy

Park

Lee

2019

Int J of Nursing Practice

View full text Add to dashboard Cite

show abstract

“…Several other locally administered products have been introduced in purpose to reduce the severity of oral mucositis but none has proven superior to the others and the effect is still very low. In melphalan‐containing chemotherapy protocols, the use of cryotherapy with ice chips has been shown to significantly reduce the severity of oral mucositis . Consequently, only supportive therapies are currently available against severe oral mucositis, such as analgesic medication and parenteral administration of fluids and nutrition.…”

Section: Introductionmentioning

confidence: 99%

Granulocyte transfusions could benefit patients with severe oral mucositis after allogeneic hematopoietic stem cell transplantation

et al. 2019

View full text Add to dashboard Cite

Background and objectives Mucositis is a common complication after allogeneic hematopoietic stem cell transplantation (HSCT), and is caused by a combination of conditioning‐induced mucosal damage and severe neutropenia. The symptoms include oral and abdominal pain, inability to swallow food and fluids, and severe diarrhoea. Severe mucositis is associated with increased risk of Graft‐versus‐Host disease and infection. Granulocyte transfusions (GCX) could be a treatment option, and our objective was to study its feasibility and potential benefits. Material and methods This retrospective, single‐centre study included 30 patients receiving GCX because of severe oral mucositis after HSCT during 2005–2017. Clinical outcome, response to GCX, change in opiate administration and adverse events were studied. Results Twenty‐seven patients received GCX from donors pre‐treated with steroids and G‐CSF, and three from donors pre‐treated with steroids only. Overall response was 83% (24/29 evaluable patients). Fifteen patients reached a complete response. In 14 of 24 responders, a reduction of the administration of opiate pain relief was seen. In eight patients this reduction was ≥50% of the dose. Adverse events (AEs) were reported in 14 cases, and were mild to moderate, and well manageable with symptomatic treatment. No life‐threatening or fatal AEs were recorded. Conclusions These results indicate that GCX could be a safe and effective treatment for oral mucositis after HSCT with the potential to reduce the necessity of opiate analgesic treatment in this disorder. No severe AEs were seen in this study, but the risk for severe pulmonary AEs after GCX needs to be considered.

show abstract

Multiple Myeloma

Merz¹,

Merz²,

Hillengaß³

et al. 2021

Blood and Marrow Transplant Handbook

View full text Add to dashboard Cite

Cryotherapy reduces oral mucositis and febrile episodes in myeloma patients treated with high-dose melphalan and autologous stem cell transplant: a prospective, randomized study

Cited by 30 publications

References 15 publications

Meta‐analysis of oral cryotherapy in preventing oral mucositis associated with cancer therapy

Meta‐analysis of oral cryotherapy in preventing oral mucositis associated with cancer therapy

Granulocyte transfusions could benefit patients with severe oral mucositis after allogeneic hematopoietic stem cell transplantation

Multiple Myeloma

Contact Info

Product

Resources

About